M8891 is an orally active, reversible and brain penetrant MethionineAminopeptidase-2 (MetAP-2) inhibitor(IC50 :54nM;Ki:4.33 nM).M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral acti
Relzomostat is a MetAP2 inhibitor, specifically targeting methionineaminopeptidase 2. It holds potential in research concerning obesity, type 2 diabetes, and other conditions associated with obesity.
Fumarranol is an angiogenesis inhibitor. It also interacts with P. falciparum methionineaminopeptidase 2 to inhibit malaria parasite growth in vitro and in vivo.
PPI-2458 is a synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionineaminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class.
A-357300 is a potent, selective, reversible MetAP2 inhibitor with IC50 of 0.12 uM. Methionineaminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.